Investigational Drug Details
| Drug ID: | D117 |
| Drug Name: | EDP-305 |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | 1933507-63-1 |
| Repositioning for NAFLD: | No |
| SMILES: | O[C@H]1[C@@H]2[C@@H]([C@@]3([C@H]([C@H]1CC)C[C@@H](CC3)O)C)CC[C@]1([C@H]2CC[C@@H]1[C@@H](CCNC(=O)NS(=O)(=O)c1ccc(cc1)C(C)(C)C)C)C |
| Structure: |
|
| InChiKey: | SJKLCUGQVVYDCX-HRNVLBFRSA-N |
| Molecular Weight: | 630.936 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | FXR agonist |
| Therapeutic Category: | Enhance lipid metabolism |
| Clinical Trial Progress: | Phase 2 completed (NCT03421431: Non-alcoholic fatty liver disease is a chronic hepatic disease that can progress to non-alcoholic steatohepatitis (NASH), which is associated with an increased risk of cirrhosis and liver cancer. Results from this phase II study support continued development of EDP-305, an oral farnesoid X receptor agonist, for the treatment of patients with NASH.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0157 | NCT04378010 | Phase 2 | Recruiting | No Results Available | January 27, 2020 | June 11, 2021 | Details |
| L0182 | NCT03421431 | Phase 2 | Completed | Has Results | April 25, 2018 | September 16, 2021 | Details |
| L0277 | NCT02918929 | Phase 1 | Completed | No Results Available | September 2016 | August 21, 2017 | Details |
| L0306 | NCT03783897 | Phase 1 | Completed | No Results Available | November 27, 2018 | July 24, 2019 | Details |
| L0307 | NCT03748628 | Phase 1 | Completed | No Results Available | October 5, 2018 | November 21, 2018 | Details |
| L0309 | NCT03610945 | Phase 1 | Completed | No Results Available | July 19, 2018 | December 5, 2018 | Details |
| L0310 | NCT03213145 | Phase 1 | Completed | No Results Available | July 11, 2017 | November 6, 2017 | Details |
| L0438 | EUCTR2019-003876-38-GB | Phase 2 | Authorised | No Results Available | 04/02/2020 | 13 July 2020 | Details |
| L0439 | EUCTR2019-003876-38-DE | Phase 2 | Not Recruiting | No Results Available | 03/02/2020 | 8 November 2021 | Details |
| L0493 | EUCTR2017-004365-27-GB | Phase 2 | Not Recruiting | No Results Available | 04/07/2018 | 16 December 2019 | Details |
| L0496 | EUCTR2017-004365-27-FR | Phase 2 | Not Recruiting | No Results Available | 02/07/2018 | 10 December 2019 | Details |
| L0528 | NCT03207425 | Phase 1 | Not recruiting | No Results Available | 30/06/2017 | 16 December 2017 | Details |
| L0542 | NCT03187496 | Phase 1 | Not recruiting | No Results Available | 01/06/2017 | 16 December 2017 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A01456 | 34740705 | J Hepatol | EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. | Details |
| A42623 | 33985820 | J Hepatol | FXR agonists for NASH: How are they different and what difference do they make? | Details |
| A48652 | 32329946 | Liver Int | A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. | Details |
| A51316 | 35675500 | Clin Transl Sci | Assessment of drug-drug interaction potential with EDP-305, a farnesoid X receptor agonist, in healthy subjects. | Details |